Thus, combination therapy with a statin and RAS blockade (i.e., using either an ARB or ACEI) to increase circulating TLR4-responsive miRNAs would potentially induce down-regulation of TLR4 activity in CAD patients [196]. This evidence concerns the gene TLR4 and coronary artery disorder.